Lung Cancer Therapeutics Market Overview
The global lung cancer therapeutics market was valued at approximately US$28.20 billion in 2025 and is projected to reach US$65.55 billion by 2035, growing at a CAGR of 8.8% during 2026–2035.
Lung cancer therapeutics comprise pharmaceutical and biological treatments used across non-small cell lung cancer, or NSCLC, and small cell lung cancer, or SCLC. The market includes chemotherapy, immune-checkpoint inhibitors, targeted small molecules, monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, antiangiogenic medicines and other emerging drug modalities.
The market is moving from broad histology-based treatment toward increasingly precise patient segmentation. Revenue is determined by disease stage, histological subtype, biomarker prevalence, testing access, treatment line, product eligibility, treatment duration, country reimbursement and the emergence of drug resistance.
Lung cancer remains the world’s most frequently diagnosed cancer and the leading cause of cancer mortality. Almost 2.5 million people were diagnosed in 2022, while more than 1.8 million died from the disease.
This report measures manufacturer-level net pharmaceutical and biological therapy revenue attributable to lung cancer. It excludes screening, diagnostic testing, surgery, external-beam radiotherapy, radiation equipment, hospital procedure fees, and general supportive-care services unless separately identified.
Lung Cancer Therapeutics Market Scope
| Metrics | Details |
| Market Size in 2025 | US$28.20 Billion |
| Forecast Value in 2035 | US$65.55 Billion |
| CAGR | 8.80% |
| By Disease | Non-Small Cell Lung Cancer and Small Cell Lung Cancer |
| By Histology | Adenocarcinoma, Squamous Cell Carcinoma, Large-Cell Carcinoma and Other Histologies |
| By Stage | Resectable Early Stage, Unresectable Stage III, Metastatic Disease, Recurrent Disease and Relapsed or Refractory Disease |
| By Therapy | Chemotherapy, Checkpoint Inhibitors, Targeted Small Molecules, Monoclonal Antibodies, ADCs, Bispecific Antibodies and Other Emerging Therapies |
| By Biomarker | EGFR, ALK, ROS1, KRAS, BRAF, MET, RET, NTRK, HER2, PD-L1, DLL3 and Other Targets |
| By Treatment Line | Neoadjuvant, Adjuvant, Consolidation, First Line, Maintenance, Second Line and Later Line |
| By Route | Oral, Intravenous, Subcutaneous, Intramuscular, Intratumoral and Other Routes |
| By Channel | Hospital and Cancer-Center Pharmacies, Buy-and-Bill, Specialty Pharmacies, Government Procurement, Retail and Mail-Order Channels |
| By Region | North America, Europe, Asia-Pacific, South America, Middle East and Africa |
| Largest Market | North America |
| Fastest-Growing Region | Asia-Pacific |
| Report Coverage | Patient Funnels, Biomarkers, Products, Treatment Sequences, Pipeline, Pricing, Patents, Access and Competitive Strategy |
Market Definition and Exclusions
The lung cancer therapeutics market includes pharmaceutical and biological products prescribed specifically for NSCLC and SCLC.
Included revenue comprises:
- Lung-cancer-attributable branded drug sales
- Generic chemotherapy
- Oncology biosimilars
- Immune-checkpoint inhibitors
- Biomarker-directed targeted therapies
- Antibody-drug conjugates
- Bispecific antibodies and T-cell engagers
- Antiangiogenic therapies
- Emerging cancer vaccines and other investigational drug modalities after approval
The market excludes:
- External-beam radiotherapy
- Radiation-treatment equipment
- Surgery
- Screening and diagnostic imaging
- Companion-diagnostic revenue
- Hospital administration charges
- General clinical-trial expenditure
- Pipeline asset valuation
- Revenue from other indications of multi-indication oncology products
Products such as Keytruda, Opdivo, Tecentriq and Imfinzi are allocated only according to the portion of revenue attributable to lung cancer indications.
Lung Cancer Therapeutics Market Key Takeaways
- The market is expected to create US$37.35 billion in additional annual revenue opportunities between 2025 and 2035.
- NSCLC generates the majority of market revenue because it represents the largest disease population and contains numerous biomarker-defined treatment segments.
- SCLC remains smaller but is gaining commercial importance through checkpoint inhibitors, maintenance combinations and DLL3-directed therapies.
- Chemotherapy continues to serve as a backbone treatment, especially in SCLC, driver-negative NSCLC and markets with limited access to premium medicines.
- Targeted therapies are increasingly segmented by EGFR, ALK, ROS1, KRAS, MET, RET, BRAF, HER2 and other actionable alterations.
- ADCs and bispecific antibodies are creating new revenue pools in patients who progress after targeted therapy or chemotherapy.
- North America remains the largest market because of advanced biomarker testing, high innovative-drug penetration and rapid adoption of FDA-approved therapies.
- Asia-Pacific is projected to grow fastest because of high disease burden, greater testing access, domestic pharmaceutical innovation and improving reimbursement.
Patient- and Product-Based Market Model
The lung cancer market should be calculated using a bottom-up patient model.
For each country, histology, stage and biomarker:
Diagnosed patients × treatment-stage eligibility × testing rate × biomarker positivity × treatment penetration × treatment duration × manufacturer net price = market revenue
A complete market funnel includes:
- Incident lung cancer cases
- Diagnosed patients
- NSCLC or SCLC classification
- Histological subtype
- Disease stage
- Biomarker-testing eligibility
- Successfully tested patients
- Biomarker-positive or driver-negative population
- Treatment-line eligibility
- Reimbursed patients
- Product penetration
- Treatment duration
- Net revenue per patient
This approach is essential because total lung cancer incidence does not equal the addressable population for any single therapy.
Lung Cancer Therapeutics Market Dynamics
Rising Lung Cancer Burden Supports Treatment Demand
Lung cancer accounted for approximately 12.4% of all new cancer cases worldwide in 2024 and caused about 18.7% of global cancer deaths.
Smoking remains the principal risk factor, while air pollution, occupational exposures, ageing and inherited susceptibility also contribute to disease incidence. IARC estimates that tobacco smoking is responsible for approximately 85% of lung cancer cases.
The market impact of increasing incidence depends on whether patients are diagnosed early, undergo biomarker testing and gain access to appropriate therapies.
Biomarker-Guided Treatment Expands Commercial Segments
Precision oncology has divided NSCLC into smaller but commercially important molecular groups.
Priority biomarkers include:
- EGFR
- ALK
- ROS1
- KRAS G12C
- BRAF V600E
- MET exon 14 skipping
- MET amplification
- RET
- NTRK
- HER2 mutations
- PD-L1
- c-Met protein overexpression
For each biomarker, commercial performance depends on prevalence, testing rate, approved treatment lines, resistance patterns and reimbursement.
Earlier-Stage Use Increases Revenue
Targeted therapies and checkpoint inhibitors are moving from metastatic disease into:
- Neoadjuvant treatment
- Adjuvant treatment
- Perioperative treatment
- Consolidation after chemoradiotherapy
- Maintenance therapy
Earlier treatment can increase eligible patient numbers and treatment duration without a proportional increase in incidence.
High Treatment Cost Restricts Access
Modern lung cancer regimens may combine:
- Biomarker testing
- A targeted agent or biologic
- Chemotherapy
- Infusion or administration
- Imaging
- Supportive medicines
High total-regimen cost limits adoption in markets with restricted insurance or reimbursement. Approval therefore does not automatically translate into commercial penetration.
Resistance Creates New Market Opportunities
Resistance limits the durability of targeted treatment but creates demand for next-generation therapies.
Important resistance pathways include:
- EGFR C797S
- MET amplification
- HER2 amplification
- Histological transformation
- Secondary ALK mutations
- Bypass signaling
- KRAS resistance
- Immune escape
- Antigen loss
The market is increasingly shaped by therapies designed for patients who progress after first-generation or standard targeted treatment.
Disease-Type Analysis
Non-Small Cell Lung Cancer
NSCLC represents the largest disease segment.
Major histological groups include:
- Adenocarcinoma
- Squamous cell carcinoma
- Large-cell carcinoma
- Other NSCLC
NSCLC revenue is driven by targeted therapies, checkpoint inhibitors, ADCs, bispecific antibodies, chemotherapy and antiangiogenic products.
Each histological group differs in:
- Biomarker prevalence
- Treatment options
- Testing strategy
- Product eligibility
- Revenue per patient
Small Cell Lung Cancer
SCLC is divided into:
- Limited-stage disease
- Extensive-stage disease
- Relapsed or refractory disease
Chemotherapy has historically dominated treatment, but the market is changing through immunotherapy, maintenance strategies and DLL3-directed products.
On November 19, 2025, the FDA converted Imdelltra, or tarlatamab, to traditional approval for adults with extensive-stage SCLC progressing on or after platinum chemotherapy.
Stage-Based Analysis
Early and Resectable NSCLC
Treatment may include:
- Surgery
- Neoadjuvant systemic therapy
- Adjuvant chemotherapy
- Adjuvant targeted therapy
- Perioperative immunotherapy
Only pharmaceutical revenue is included in the market, while surgery is excluded.
Unresectable Stage III NSCLC
Patients may receive chemoradiotherapy followed by consolidation immunotherapy. Radiation procedure revenue remains outside the market.
Metastatic NSCLC
Metastatic treatment is segmented by:
- Actionable driver mutation
- PD-L1 expression
- Histology
- Performance status
- Previous therapy
This remains the largest revenue-generating setting because of prolonged treatment with targeted agents and checkpoint inhibitors.
Limited- and Extensive-Stage SCLC
Limited-stage treatment is still based heavily on chemoradiotherapy, while extensive-stage treatment includes chemo-immunotherapy and maintenance strategies.
Treatment-Type Analysis
Chemotherapy
Chemotherapy remains a core component of lung cancer treatment.
Important agents include:
- Platinum compounds
- Pemetrexed
- Taxanes
- Etoposide
- Gemcitabine
- Other cytotoxic products
It remains particularly important in SCLC, driver-negative disease, combination regimens, and price-sensitive markets.
The original page estimated that chemotherapy represented 38.24% of the market, although that share requires validation against updated immunotherapy and targeted-product revenue.
Immune-Checkpoint Inhibitors
Checkpoint therapies target:
- PD-1
- PD-L1
- CTLA-4
- Emerging immune pathways
Major products include:
- Keytruda
- Opdivo
- Imfinzi
- Tecentriq
Revenue growth is supported by earlier treatment lines, combinations, maintenance use and new formulations.
Targeted Small Molecules
Major targeted-therapy classes include:
- EGFR inhibitors
- ALK inhibitors
- ROS1 inhibitors
- KRAS inhibitors
- MET inhibitors
- RET inhibitors
- BRAF/MEK inhibitors
- NTRK inhibitors
- HER2-directed small molecules
Oral administration and strong activity in selected biomarkers support premium commercial value.
Antibody-Drug Conjugates
ADCs deliver a cytotoxic payload through a tumor-targeting antibody.
Important lung cancer targets include:
- TROP2
- HER2
- c-Met
- CEACAM5
- Other emerging antigens
On May 14, 2025, the FDA granted accelerated approval to Emrelis for previously treated non-squamous NSCLC with high c-Met protein overexpression.
On June 23, 2025, the FDA granted accelerated approval to Datroway for locally advanced or metastatic EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum chemotherapy.
Bispecific Antibodies and T-Cell Engagers
Major categories include:
- EGFR/MET bispecific antibodies
- DLL3-directed T-cell engagers
- PD-1/VEGF bispecifics
- Other immune-engaging platforms
These therapies may offer off-the-shelf alternatives to personalized cell therapies but can require specialized toxicity monitoring.
Biomarker-Level Market Analysis
EGFR-Mutated NSCLC
EGFR-positive disease must be separated into:
- Early-stage resected disease
- Unresectable Stage III disease
- Metastatic first-line disease
- Disease after osimertinib
- Common sensitizing mutations
- Exon 20 insertion mutations
- Uncommon EGFR mutations
Products include Tagrisso, Rybrevant-based combinations and newer post-progression therapies.
ALK-Positive NSCLC
ALK-directed products include Alecensa, Lorbrena and other kinase inhibitors.
Commercial competition depends on:
- CNS activity
- First-line positioning
- Resistance mutation coverage
- Tolerability
- Patent protection
ROS1-Positive NSCLC
On June 11, 2025, the FDA approved Ibtrozi, or taletrectinib, for locally advanced or metastatic ROS1-positive NSCLC.
On July 22, 2026, the FDA approved Jideytro, or zidesamtinib, for ROS1-positive NSCLC after prior ROS1 TKI treatment, creating a new post-resistance treatment option.
KRAS G12C-Positive NSCLC
Key products include Lumakras and Krazati.
The commercial market is influenced by:
- Earlier-line development
- Combination regimens
- Resistance
- Competing KRAS inhibitors
- Safety and tolerability
MET- and HER2-Altered NSCLC
MET alterations may include exon 14 skipping, amplification and high protein expression. These populations should not be combined into one segment.
HER2-mutated NSCLC is being reshaped by targeted therapies and ADCs, including newly approved products and label expansions.
PD-L1-Defined Driver-Negative NSCLC
Driver-negative disease is segmented by:
- PD-L1 high expression
- PD-L1 low expression
- PD-L1-negative disease
- Squamous histology
- Non-squamous histology
The treatment market includes checkpoint-inhibitor monotherapy and chemotherapy-immunotherapy combinations.
Treatment-Line and Sequencing Analysis
Driver-Negative Metastatic NSCLC
Treatment pathways differ by:
- Histology
- PD-L1 status
- Contraindications
- Previous treatment
- Disease progression
EGFR-Mutated NSCLC
A commercial sequence may include:
- Adjuvant targeted therapy in eligible early-stage disease
- Targeted treatment for unresectable or metastatic disease
- Resistance testing at progression
- Biomarker-directed combination therapy
- ADC or chemotherapy treatment in later lines
SCLC
The sequence includes:
- Limited-stage chemoradiation
- Extensive-stage chemo-immunotherapy
- Maintenance treatment
- Platinum-sensitive or resistant relapse
- DLL3-directed therapy and later-line products
Product-Level Commercial Intelligence
Core products include:
- Tagrisso
- Keytruda
- Imfinzi
- Opdivo
- Tecentriq
- Alecensa
- Rybrevant
- Lazcluze
- Enhertu
- Datroway
- Imdelltra
- Lumakras
- Krazati
- Tabrecta
- Tepmetko
- Gavreto
- Retevmo
- Rozlytrek
- Lorbrena
- Zepzelca
- Ibtrozi
- Emrelis
- Jideytro
For every product, the full report evaluates:
- Company
- Mechanism
- Biomarker
- Histology
- Stage
- Treatment line
- Approval geography
- Route
- Dosing
- 2025 revenue
- Lung-cancer-attributable revenue
- 2035 forecast
- Patent expiry
- Competitors
- Label-expansion opportunity
- Resistance risk
2025–2026 Market Developments
May 14, 2025 - Emrelis
The FDA granted accelerated approval to AbbVie’s Emrelis for previously treated, locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression. The approval created a biomarker-defined ADC market requiring an FDA-approved c-Met test.
June 11, 2025 - Ibtrozi
The FDA approved Nuvation Bio’s Ibtrozi for locally advanced or metastatic ROS1-positive NSCLC, increasing competition in a small but high-value genomic segment.
June 23, 2025 - Datroway
The FDA granted accelerated approval to Datroway for previously treated EGFR-mutated NSCLC, expanding ADC use after targeted therapy and platinum chemotherapy.
October 2, 2025 - Zepzelca Maintenance Combination
The FDA approved lurbinectedin with atezolizumab or subcutaneous atezolizumab for maintenance treatment of extensive-stage SCLC without progression after first-line induction. The approval expands maintenance revenue beyond initial chemo-immunotherapy.
November 19, 2025 - Imdelltra
The FDA granted traditional approval to Imdelltra for previously treated extensive-stage SCLC, strengthening the commercial role of DLL3-directed T-cell engagers.
July 22, 2026 - Jideytro
The FDA approved Jideytro for locally advanced or metastatic ROS1-positive NSCLC following prior ROS1 TKI treatment. This creates a new post-resistance market and increases competition in ROS1-directed therapy.
Pipeline and Probability-Adjusted Forecasting
Pipeline assets are classified as:
- Submitted or under review
- Phase III
- Phase II
- Phase I
- Preclinical
- Discontinued
- Partnered
- Rights returned
The pipeline database should include:
- Asset
- Company
- Target
- Modality
- Disease subtype
- Stage
- Treatment line
- Clinical phase
- Next catalyst
- Probability
- Expected launch
- Peak-sales estimate
FDA’s oncology approval database should be used as the official source for updated US regulatory decisions, although FDA notes that not every label update is separately announced.
Patent and Exclusivity Analysis
High-priority products for patent analysis include:
- Keytruda
- Tagrisso
- Imfinzi
- Opdivo
- Tecentriq
- Alecensa
- Older EGFR inhibitors
- Older ALK inhibitors
- Bevacizumab products
- Pemetrexed products
For every product, the report evaluates:
- Composition-of-matter expiry
- Regulatory exclusivity
- Formulation patents
- Method-of-use patents
- Litigation
- Generic or biosimilar entry
- Expected price erosion
- Product-switching strategy
- Replacement franchise
Biomarker Testing and Companion Diagnostics
Targeted-therapy forecasts depend on testing access.
Important testing methods include:
- Tissue next-generation sequencing
- Liquid biopsy
- PCR
- Immunohistochemistry
- Fluorescence in situ hybridization
- PD-L1 testing
- Comprehensive genomic profiling
Commercial variables include:
- Country testing rate
- Tissue adequacy
- Turnaround time
- Reimbursement
- Positivity yield
- Test failure
- Liquid-biopsy use
- Treatment delay
- Diagnostic partner
The Emrelis indication illustrates the dependence of therapy eligibility on an approved biomarker test for high c-Met protein expression.
Pricing and Market Access
The report evaluates:
- US list and net price
- European negotiated price
- Japan reimbursement
- China reimbursement status
- Cost per cycle
- Annual treatment cost
- Combination-regimen cost
- Testing cost
- Administration expense
- Prior authorization
- Health-technology assessment
- Patient support
Route of Administration
Oral
Oral targeted therapies dominate many biomarker-defined segments.
Advantages include home administration, while adherence, toxicity management and specialty-pharmacy access remain important.
Intravenous
Checkpoint inhibitors, chemotherapy and ADCs commonly require intravenous administration and oncology-center oversight.
Subcutaneous
Subcutaneous formulations can reduce chair time, administration costs and treatment-center burden.
Other Routes
Intramuscular, intratumoral and investigational pulmonary delivery should be analyzed separately when clinically relevant.
Distribution Channels
Recommended channels include:
- Hospital and cancer-center pharmacies
- Physician-administered buy-and-bill
- Specialty pharmacies
- Retail pharmacies for oral targeted therapies
- Government and national-health procurement
- Mail-order specialty distribution
- Named-patient programs
- Clinical-trial channels
Online pharmacies should not be treated as a universal major channel for infused checkpoint inhibitors, ADCs or bispecific antibodies.
Regional Analysis
North America
North America remains the largest market.
The original source valued North America at approximately US$10.91 billion in 2024.
Regional leadership is supported by:
- High biomarker-testing rates
- Rapid FDA approvals
- Premium drug pricing
- Broad checkpoint-inhibitor adoption
- Advanced clinical infrastructure
- Extensive buy-and-bill distribution
Asia-Pacific
Asia-Pacific is expected to record the fastest growth.
The original page estimated regional revenue of approximately US$6.09 billion in 2024.
Growth is supported by:
- High lung cancer burden
- Greater EGFR prevalence in East Asian populations
- Expanding genomic testing
- Domestic targeted therapies
- Clinical-trial activity
- Improving reimbursement
Japan, China and South Korea are major precision-oncology markets, while India and Southeast Asia require separate affordability and access assumptions.
Competitive Landscape
Immuno-Oncology Leaders
- Merck & Co.
- Bristol Myers Squibb
- AstraZeneca
- Roche
- BeiGene
Targeted-Therapy Leaders
- AstraZeneca
- Pfizer
- Roche
- Takeda
- Novartis
- Eli Lilly
- Boehringer Ingelheim
- Amgen
- Johnson & Johnson
- Nuvation Bio
- Nuvalent
- Bayer
ADC and Bispecific Leaders
- Daiichi Sankyo
- AstraZeneca
- AbbVie
- Johnson & Johnson
- Amgen
- Gilead Sciences
SCLC-Focused Participants
- Amgen
- AstraZeneca
- Roche
- Jazz Pharmaceuticals
- Merck
- Emerging DLL3-focused developers
The original company list included Pfizer, Merck, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Eli Lilly, Roche and AbbVie. The revised competitive structure groups companies by strategic modality and biomarker position.
How This Report Supports Commercial Decisions
The report helps pharmaceutical companies, biotechnology developers, investors, diagnostics companies and market-access teams evaluate:
- NSCLC and SCLC revenue through 2035
- Patient opportunity by stage and histology
- Biomarker-defined market sizes
- Product revenue and market share
- Treatment sequencing
- Resistance opportunities
- ADC and bispecific competition
- Patent and exclusivity exposure
- Pipeline launch probability
- Pricing and reimbursement
- Diagnostic testing barriers
- Company portfolio gaps
- Licensing and acquisition opportunities
Suggestions for Related Report
For more pharmaceutical-related reports, please click here
